The appropriate treatment of recurrent/residual NFP-Macs is not well established.

NFP-Macs with significant postsurgical tumor residuals contain several dopamine receptor (DR) and Somatostatin receptor (SSTR) subtypes, some with high copy numbers. The receptor composition of NFP-Macs may guide future clinical research into targeted treatment strategies to reduce residual tumor volume. Such studies would determine the potential threshold of receptor levels for response to therapy for existing dopaminergic agonists and somatostatin analogs ¹⁾.